Celebi brings more than two decades of leadership experience with biotechnology companies, most recently in the field of cancer immunotherapies.
Previously, Celebi served as the chief operating officer of X4 Pharmaceuticals where he established and oversaw the company's oncology business strategy.
He also served as chief business officer of Igenica Biotherapeutics, Inc., and as vice president of business development, new product planning and alliance management at ArQule, Inc.,
Celebi was one of the early employees at Tularik, Inc., where he conducted drug discovery and basic research for an anti-viral drug program. He received an M.B.A. from Carnegie Mellon University and a B.S. in Biophysics from the University of California, San Diego.
Privately-held Sensei is emerging with a focused immuno-oncology strategy, promising clinical data from the Phase I trial of its lead drug candidate SNS-301, and the proprietary SPIRIT drug development platform that is generating a pipeline of innovative immuno-oncology therapies.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886